Skip to main content

Table 3 Characteristics of patients with response to nivolumab

From: Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Age PS Genomic alteration PD-L1+ in TC CPS≥10 CPS≥1 EBV MMR
Mutation Amplification TMB/Mb
63 0 NE NE NE – + + – MMR-D
63 0 NE NE NE + + + – MMR-D
66 0 PIK3CA, TP53 None 38.3 + – + – MMR-D
62 0 PIK3CA None 11.5 – – + – MMR-D
53 1 None None 7.7 + + + – MMR-D
79 0 MET, PIK3CA, TP53 None 58.0 + – + – MMR-D
64 0 PIK3CA None 15.3 + + + – MMR-P
74 0 ARID1A, TP53 CCNE1 15.1 – – + – MMR-P
80 0 TP53 CCNE1 11.5 – – + – MMR-P
76 0 None None 10.1 – – + – MMR-P
73 0 TP53 None 5.0 + + + – MMR-P
65 0 NE NE NE + + + – MMR-P
53 0 NE NE NE + – + – MMR-P
43 0 TP53 None 7.7 – – + + MMR-P
  1. CPS combined positive score, EBV Epstein-Barr virus, MMR mismatch repair, MMR-D mismatch repair deficient, MMR-P mismatch repair proficient, NE not examined, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, PS Eastern Cooperative Oncology Group performance status, TMB tumor mutation burden
Back to article page